Deucravacitinib in Moderate-to-severe Psoriasis

Immunotherapy. 2022 doi: 10.2217/imt-2022-0109

Deucravacitinib demonstrates promising results as a TYK2-specific immunotherapy and shows considerable efficacy yet is able to avoid the side effect profile observed with other JAK inhibitors.

Overall, deucravacitinib has been shown to be a promising new oral therapy for moderate to severe plaque psoriasis and psoriatic arthritis and is currently FDA-approved for use in moderate to severe plaque psoriasis. Side effects with deucravacitinib include nasopharyngitis, headache, diarrhoea, nausea, and upper respiratory tract infection. Further research is necessary to confirm the validity of these potential downstream effects.